Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Belite Bio announced that data on its lead candidate Tinlarebant will be presented at the ISCEV Annual Symposium in Sydney and the ASRS Annual Meeting in Montréal. Professor John Grigg will present topline results from the Phase 3 DRAGON study in adolescent Stargardt’s Disease on July 8, while Dr. Paul Bernstein will present Phase 3 DRAGON trial results on July 18.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.